First human test of mRNA RSV shot begins
NCT ID NCT06573281
Summary
This is the first time this new mRNA vaccine for Respiratory Syncytial Virus (RSV) is being tested in people. The study aims to check if different doses are safe and if they trigger a good immune response in 213 healthy adults aged 18-45. Researchers will closely monitor for side effects and measure antibody levels in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Rolling Hills Estates, California, 90274, United States
-
GSK Investigational Site
Atlanta, Georgia, 30281, United States
-
GSK Investigational Site
Lenexa, Kansas, 66219, United States
-
GSK Investigational Site
Omaha, Nebraska, 68134, United States
-
GSK Investigational Site
Rochester, New York, 14609, United States
-
GSK Investigational Site
Camberwell, Victoria, 3124, Australia
-
GSK Investigational Site
Madrid, 28006, Spain
-
GSK Investigational Site
Madrid, 28046, Spain
-
GSK Investigational Site
Madrid, 28222, Spain
Conditions
Explore the condition pages connected to this study.